Skip to main content
EVFM
OTC Life Sciences

Evofem Biosciences Reports Deepening Q1 Losses, Reiterates Going Concern Warning Amid Severe Liquidity Crisis

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Biotech Stocks · Healthcare
Sentiment info
Negative
Importance info
10
Price
$0.007
Mkt Cap
$887.951K
52W Low
$0.001
52W High
$0.02
52W Position info
737% above low
Off High info
66% below high
Rel. Volume info
0.4× avg
Market data snapshot near publication time

EVFM has more than doubled off its 52-week low of $0.001.

Summary

Evofem Biosciences reported a substantial Q1 net loss and reiterated its going concern warning, highlighting severe liquidity issues, ongoing debt defaults, and massive potential dilution, despite a new distribution deal.


Key Events · Earnings and Guidance · EVFM

  • Deepening Net Loss

    Reported a Q1 2026 net loss of $(5.485) million, a significant decline from a $0.956 million net income in Q1 2025.

  • Going Concern Warning

    Management explicitly stated that current liquidity is insufficient to fund operations for the next 12 months, raising substantial doubt about the company's ability to continue as a going concern.

  • Severe Dilution Potential

    The capital structure includes potentially dilutive securities equivalent to over 6.7 billion shares, compared to 132.5 million shares outstanding, indicating extreme future dilution risk.

  • Ongoing Debt Defaults

    The company is in an active dispute over a $107 million accelerated debt repayment claim from Future Pak LLC, which it intends to contest.


Analysis · EVFM · Life Sciences

Evofem Biosciences' Q1 2026 results show a significant deterioration in financial health, with a net loss of $5.485 million compared to a profit in the prior year. The company explicitly states it lacks sufficient liquidity to fund operations for the next 12 months, raising substantial doubt about its ability to continue as a going concern. This is compounded by ongoing disputes over a $107 million accelerated debt repayment claim and the potential for over 6.7 billion shares of future dilution, far exceeding current outstanding shares. While a new distribution agreement for SOLOSEC in Africa offers a minor positive, it is dwarfed by the company's critical financial distress and the failure of a proposed merger.

How filings like this one have moved

In the 30 days to Nov 11, 2026, 40% of the 30 measured filings Wiseek scored 10 moved their stock by 5% or more by the next session's close. The median move was +0.45%. These are measured outcomes after filings of this importance, not a forecast for this one.

Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset

At the time of this filing, EVFM was trading at $0.01 on OTC in the Life Sciences sector, with a market capitalization of approximately $888K. The 52-week trading range was $0.00 to $0.02. This filing was assessed with negative market sentiment and an importance score of 10 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

EVFM - Latest Insights

EVFM
Oct 15, 2026, 4:05 PM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $0.0070
Real-time Price: $0.0061 info
Change: -$0.0009 (-13%) info
Market Cap: $808.433K info
EVFM
Sep 23, 2026, 5:08 PM EDT
Source: Reuters
Importance Score:
7
Price at Filing: $0.0077
Real-time Price: $0.0061 info
Change: -$0.0016 (-21%) info
Market Cap: $808.433K info
EVFM
Aug 14, 2026, 4:06 PM EDT
Filing Type: 10-Q
Importance Score:
9
Price at Filing: $0.007524
Real-time Price: $0.0061 info
Change: -$0.001424 (-19%) info
Market Cap: $808.433K info
EVFM
Jul 14, 2026, 4:33 PM EDT
Source: Wiseek News
Importance Score:
7
Price at Filing: $0.0083
Real-time Price: $0.0061 info
Change: -$0.0022 (-27%) info
Market Cap: $808.433K info
EVFM
Jul 14, 2026, 4:31 PM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $0.0083
Real-time Price: $0.0061 info
Change: -$0.0022 (-27%) info
Market Cap: $808.433K info